What Is the Difference Between APS Criteria and Diagnosis?

When you read about Antiphospholipid Syndrome (APS) online, you will likely encounter scoring systems like the 2006 Sydney criteria or the 2023 ACR/EULAR criteria. It is very common to feel confused if the diagnosis your doctor gives you does not perfectly match these lists.

The key difference lies in their purpose: classification criteria are strict scoring systems designed to create uniform groups of patients for research studies, whereas a clinical diagnosis is an individualized medical decision made by your doctor based on your unique health history ^[1][2]. Importantly, a positive antibody test does not automatically equal an APS diagnosis; a true diagnosis requires both significant laboratory findings and a confirmed clinical event, like a blood clot or specific pregnancy complication ^[3].

Key Terms You Will See

To understand the criteria, it helps to know the three main antiphospholipid antibodies (aPL) tested:

• Lupus Anticoagulant (LA): Despite the confusing name, this is a laboratory antibody finding associated with a higher risk of clotting, not a blood-thinning medication.
• Anticardiolipin (aCL): An antibody often measured for its level (titer).
• Anti-β2-glycoprotein I (anti-β2GPI): Another antibody measured by its level.

The Purpose of Classification Criteria

Classification criteria are designed by researchers to ensure that clinical trials compare “apples to apples.” They prioritize being absolutely certain that everyone in a study has identical disease features (high specificity), even if that means leaving out some people who genuinely have the condition ^[2][4].

There are two main sets of criteria you might see:

• The 2006 Sydney Criteria: This older system requires at least one qualifying clinical event (like a confirmed blood clot) and at least one persistently positive antiphospholipid antibody test, taken at least 12 weeks apart ^[2][3].
• The 2023 ACR/EULAR Criteria: This newer framework uses a complex, weighted point system. A patient must first have a positive antibody test within three years of a qualifying clinical event (not just any general symptom). From there, they must accumulate at least three points in clinical categories and three points in laboratory categories ^[2].

The 2023 criteria favor specificity for research ^[4]. Because of this, some patients who clearly have a clinically valid disease—or who would have been classified under the older Sydney criteria—will not meet the new 2023 point thresholds ^[5].

How a Clinical Diagnosis Works

While researchers need strict rules to study new treatments, your doctor’s primary goal is to evaluate your individual risks. A clinical diagnosis does not rely on a pass/fail calculator. Instead, your clinician evaluates your entire health picture ^[1][6].

Your doctor will consider factors that research criteria might weigh differently:

• Non-Criteria and Supportive Manifestations: The 2023 criteria do include clinical domains for issues like thrombocytopenia (low blood platelets) and heart valve disease, but they carry less weight than major clots ^[2]. Other supportive findings, like livedo reticularis (a lacy, net-like purplish skin discoloration), kidney disease, or neurological symptoms, are not specific to APS and usually cannot establish a diagnosis on their own ^[7][8]. However, your doctor uses these as important clues to support your overall assessment.
• Antibody Persistence: The 2006 criteria strictly require tests spaced 12 weeks apart, while the 2023 criteria focus on an initial test within a specific timeframe of a clinical event ^[2][9]. In real-world practice, doctors use repeat testing to confirm that your antibodies are persistently positive, rather than just a temporary spike from a passing infection ^[10][11].
• Medication Interference: Medications can affect your lab results. Different blood thinners (like warfarin, heparins, or direct oral anticoagulants) interfere with the lupus anticoagulant test in different ways ^[12]. Never stop or alter your blood thinners to get a “clean” test result without strict supervision from your doctor, as doing so can cause a dangerous, life-threatening clot.
• Family History: Because you are exploring familial APS, it is important to know that a family history of the disease helps your doctor assess your overall risk. However, family history alone does not establish an APS diagnosis; you still need the combination of a clinical event and positive antibodies ^[1].

Why You Shouldn’t “Self-Score”

Because the 2023 ACR/EULAR criteria use a point system, it can be tempting to add up your own score. However, these criteria were never meant to be a diagnostic checklist ^[6]. Failing to reach a research threshold does not invalidate your symptoms or mean that no explanation is needed.

Furthermore, treatment is highly individualized. Being aPL-positive or failing a classification threshold does not automatically mean you need—or don’t need—lifelong blood thinners. An expert clinician balances your lab results, your pregnancy history, and your specific clotting risks to create a safe management plan for you ^[13][5].

EMERGENCY WARNING SIGNS
Whether you have an official APS diagnosis or are still being evaluated, seek emergency medical care immediately if you experience signs of a blood clot, including:

• Sudden shortness of breath or chest pain
• Coughing up blood
• A newly swollen, red, or painful arm or leg (usually on one side)
• Sudden weakness, numbness, or trouble speaking